Kidder Stephen W Purchases 2,544 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Kidder Stephen W grew its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 33.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 10,248 shares of the pharmaceutical company's stock after acquiring an additional 2,544 shares during the quarter. Vertex Pharmaceuticals accounts for about 1.2% of Kidder Stephen W's holdings, making the stock its 26th largest position. Kidder Stephen W's holdings in Vertex Pharmaceuticals were worth $4,127,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of VRTX. Dunhill Financial LLC boosted its stake in Vertex Pharmaceuticals by 70.6% in the 3rd quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company's stock valued at $27,000 after buying an additional 24 shares in the last quarter. Legacy Investment Solutions LLC acquired a new stake in shares of Vertex Pharmaceuticals in the 3rd quarter valued at $33,000. Brown Lisle Cummings Inc. bought a new stake in shares of Vertex Pharmaceuticals in the 4th quarter worth about $30,000. Sugar Maple Asset Management LLC acquired a new stake in shares of Vertex Pharmaceuticals during the 4th quarter worth about $35,000. Finally, Golden State Wealth Management LLC acquired a new position in Vertex Pharmaceuticals in the fourth quarter valued at about $37,000. Institutional investors and hedge funds own 90.96% of the company's stock.

Insider Transactions at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, EVP David Altshuler sold 3,231 shares of the business's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $500.00, for a total transaction of $1,615,500.00. Following the sale, the executive vice president now directly owns 26,512 shares of the company's stock, valued at $13,256,000. The trade was a 10.86 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Ourania Tatsis sold 244 shares of the firm's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $455.06, for a total value of $111,034.64. Following the completion of the transaction, the executive vice president now owns 67,695 shares of the company's stock, valued at $30,805,286.70. The trade was a 0.36 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 4,315 shares of company stock valued at $2,121,012 over the last three months. Company insiders own 0.20% of the company's stock.

Remove Ads

Vertex Pharmaceuticals Stock Down 0.5 %

VRTX traded down $2.43 during trading on Wednesday, reaching $469.94. The company had a trading volume of 1,024,497 shares, compared to its average volume of 1,515,050. The company has a market cap of $120.68 billion, a P/E ratio of -213.55, a PEG ratio of 2.11 and a beta of 0.50. Vertex Pharmaceuticals Incorporated has a 12 month low of $377.85 and a 12 month high of $519.88. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.69 and a quick ratio of 2.35. The business's fifty day moving average price is $483.41 and its 200 day moving average price is $463.75.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its quarterly earnings data on Monday, February 10th. The pharmaceutical company reported $3.54 EPS for the quarter, missing the consensus estimate of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%. Equities analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $480.00 price objective on shares of Vertex Pharmaceuticals in a report on Tuesday, February 11th. Stifel Nicolaus boosted their price objective on Vertex Pharmaceuticals from $490.00 to $494.00 and gave the stock a "hold" rating in a research note on Monday, December 16th. Royal Bank of Canada lifted their price target on Vertex Pharmaceuticals from $408.00 to $420.00 and gave the company a "sector perform" rating in a report on Tuesday, April 1st. HC Wainwright reissued a "buy" rating and set a $550.00 price objective on shares of Vertex Pharmaceuticals in a report on Tuesday, February 11th. Finally, Truist Financial boosted their target price on shares of Vertex Pharmaceuticals from $460.00 to $520.00 and gave the stock a "buy" rating in a research note on Tuesday, February 11th. Ten research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Vertex Pharmaceuticals has a consensus rating of "Moderate Buy" and an average price target of $509.17.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.